How to access Adbry for moderate-to-severe atopic dermatitis from the UAE: 2026 pathway via UAE dermatology and pharmacy supply
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
The UAE has one of the deepest dermatology service networks in the wider region. Cleveland Clinic Abu Dhabi, Mediclinic City and Mediclinic Parkview, NMC and Aster Hospitals across Dubai and Sharjah, Burjeel Medical City, Saudi German Hospital Dubai, and the Dr Sulaiman Al Habib network in Dubai all run dermatology services that treat moderate-to-severe atopic dermatitis from topical regimens through systemic immunosuppressants and into the biologic era. Dupixent (dupilumab) has been the most-prescribed biologic for atopic dermatitis in the UAE for several years; Adbry (tralokinumab-ldrm) is the IL-13-selective alternative, registered with the Emirates Drug Establishment and increasingly part of the dermatologist's biologic shortlist. For a UAE-resident adult or adolescent (12+) with moderate-to-severe AD that has plateaued on topical prescription therapy, the operational question is no longer whether IL-13-targeted biologic therapy is reachable: it is whether Adbry or Dupixent or one of the oral JAK inhibitors is the right fit, how the prescription is dispensed, what insurance will and will not cover, and how the family handles the self-injection routine over a multi-year treatment course.
This page explains how the pathway works in 2026 for a UAE-resident patient: who qualifies, where the prescribing dermatologist conversation happens, how Adbry is dispensed and stored, what the loading-to-maintenance dosing schedule looks like, what the realistic out-of-pocket exposure band is in AED, what to monitor (conjunctivitis being the notable adverse event class), and how the longer-term treatment course fits into a UAE family's life. It is concierge documentation written for a family that is already in conversation with a treating dermatologist and wants the operational reality laid out plainly.
Why Adbry, and why now
Adbry is tralokinumab-ldrm, a fully human IgG4 monoclonal antibody that selectively binds to and neutralises the IL-13 cytokine itself. Developed by LEO Pharma, originated at MedImmune. The mechanism is what distinguishes Adbry from Dupixent: Dupixent blocks the IL-4Rα receptor and therefore inhibits both IL-4 and IL-13 signalling; Adbry binds the IL-13 cytokine directly and produces a more selective IL-13 blockade. For patients whose AD biology is IL-13-dominant, this selectivity can translate into comparable efficacy with a different side-effect profile.
The FDA approved Adbry for adults with moderate-to-severe atopic dermatitis in December 2021, then expanded the label to adolescents aged 12 to 17 in December 2023. The pivotal trials (ECZTRA 1, 2, 3, and 6) demonstrated EASI-75 response rates around 25 to 56 percent at week 16, depending on monotherapy versus topical-corticosteroid-combination arms and adult versus adolescent cohorts. Long-term extension data shows maintained response through week 52 with every-2-week or every-4-week dosing.
For a UAE patient who has cycled through topical corticosteroids of varying strength, topical calcineurin inhibitors (tacrolimus or pimecrolimus), perhaps short courses of oral cyclosporine or methotrexate, and possibly a dupilumab trial that did not achieve adequate response or produced unacceptable adverse effects, Adbry is the IL-13-selective alternative. The conversation about whether to start with Adbry as first biologic, switch to Adbry from another biologic, or consider an oral JAK inhibitor (Cibinqo, Rinvoq) is the central clinical decision. This page is the operational layer underneath that conversation.
What Adbry is, in plain language
Adbry is a subcutaneous injection. There is no infusion centre, no inpatient stay, no specialty-centre referral required. After an initial training session with the prescribing dermatologist or a LEO nurse educator, the patient self-injects at home. The injection device is a prefilled syringe of 150 mg per millilitre.
The adult dosing schedule is a loading dose of 600 mg (four syringes) at week 0, then 300 mg every 2 weeks. For patients under 100 kg who achieve clear or almost-clear skin (IGA 0 or 1) after 16 weeks of treatment, the maintenance schedule can step down to 300 mg every 4 weeks. The adolescent (12 to 17) schedule is a 300 mg loading dose at week 0, then 150 mg every 2 weeks.
This is not a one-shot or short-course therapy. Adbry is taken for as long as it controls the disease. Patients who achieve a meaningful response typically stay on Adbry for years.
Eligibility at a UAE dermatologist's clinic
For UAE-resident patients, the dermatology services apply the FDA and EMA criteria with local insurance adaptation:
1. Confirmed diagnosis of moderate-to-severe atopic dermatitis (typically EASI score of 16 or greater, IGA of 3 or greater, BSA involvement of 10 percent or greater, or DLQI elevation indicating substantial quality-of-life impact). 2. Documented prior trial of topical prescription therapy (mid-to-high potency topical corticosteroids and/or topical calcineurin inhibitors) that failed to control the disease, or for which prior continuation is not advisable due to side effects or contraindication. 3. Age 12 or older and weight at least 40 kg. 4. Screening for active infection, especially helminthic parasitic infection. IL-13 blockade may interfere with helminth defence; in regions of the UAE with documented helminth exposure (less common in 2026 than historically, but still relevant for recent arrivals from helminth-endemic regions), this screening matters. 5. Tuberculosis screening per institutional standard. 6. Baseline ophthalmology assessment for patients with prior conjunctivitis history. Conjunctivitis is the notable adverse-event class for Adbry, generally mild to moderate and responsive to topical treatment. 7. Vaccination status review. Live vaccines should be avoided during treatment. 8. Pregnancy planning discussion for women of childbearing potential; data is limited.
A UAE patient should arrive at the biologic conversation with the most recent dermatology documentation: current EASI, IGA, BSA, and DLQI scores, photographs of involved skin, the complete topical-therapy history with response durations and reasons for failure, prior systemic therapy history if applicable, and the insurance preauthorisation paperwork that the dermatologist's office typically initiates.
The UAE prescribing and supply picture, plainly
Adbry is registered with the Emirates Drug Establishment. Commercial supply runs through LEO Pharma's regional distributor network. The pathway is:
1. Prescribing dermatologist: any board-certified UAE dermatologist treating moderate-to-severe AD. The major UAE private dermatology services include Cleveland Clinic Abu Dhabi, Mediclinic City and Parkview, NMC Specialty and Aster Hospitals across Dubai and Sharjah, Burjeel Medical City, Saudi German Hospital Dubai, Dr Sulaiman Al Habib network. Public sector dermatology at SKMC, Tawam, and Dubai Health Authority hospitals handles the same role for Emirati nationals. 2. Pharmacy dispensing: hospital pharmacy if prescribed in the inpatient or specialty outpatient setting; community pharmacy with cold-chain refrigeration capability for ongoing maintenance dispensing. Adbry must be stored at 2 to 8 degrees Celsius and can be at room temperature up to 14 days before use. 3. Insurance pre-authorisation: Thiqa coverage for Emirati nationals has historically extended to biologic AD therapy on a case-by-case basis with documented severity and prior-therapy failure. Daman and the major commercial insurers (Oman Insurance, AXA Gulf, MetLife, Cigna, others) require similar documentation. Some require dupilumab trial-and-failure before approving tralokinumab; this is the most common pre-authorisation friction point. 4. Self-injection training: typically a single supervised session at the prescribing dermatologist's clinic or a LEO nurse educator visit. Most patients are comfortable with self-injection after 1 to 2 sessions. 5. Ongoing monitoring: dermatology follow-up at weeks 4 and 16, then every 3 to 6 months. Ophthalmology review if conjunctivitis develops.
The 2026 pathway, step by step
Week 0 to 1: Reserve Meds builds the documentation pack with the treating dermatologist's office. We collect current severity scores, photographs, the complete topical-therapy history, prior systemic-therapy history if applicable, and insurance card details. The dermatologist's office submits insurance preauthorisation if applicable.
Week 1 to 4: Insurance preauthorisation review. Most UAE commercial insurers turn this around within 2 to 4 weeks. Some require dupilumab trial-and-failure documentation before approving tralokinumab; we surface this requirement early.
Week 4 to 6: First dispensing at the dermatologist's clinic or partner pharmacy. Loading dose of 600 mg administered in clinic with self-injection training. Patient takes home the next 2 syringes for the next dose.
Week 2 to 4 of treatment: Patient self-injects 300 mg at home. Reserve Meds coordinates the cold-chain delivery for the next month's supply.
Week 4 to 16 of treatment: Self-injection every 2 weeks. Dermatology follow-up at weeks 4 and 16 to assess response.
Week 16 onwards: Response assessment. Patients achieving IGA 0 or 1 with weight under 100 kg may step down to 300 mg every 4 weeks. Patients with partial response continue every 2 weeks. Patients with no response are reassessed and the treating dermatologist considers switching to Dupixent, an oral JAK inhibitor, or further evaluation.
Ongoing: Maintenance dosing for as long as Adbry controls the disease. Annual dermatology review at minimum; quarterly is typical for active patients.
Cost expectation in AED
US list price for Adbry is approximately USD 1,810.87 for a 2-syringe pack (one month of every-2-week dosing) or USD 3,621.73 for a 4-syringe pack (two months). Annual cost at list price is approximately USD 25,700 to 35,000, with the lower end reflecting maintenance every-4-week dosing for responding patients and the upper end reflecting every-2-week dosing throughout the year.
At 2026 indicative cross rates, the AED-equivalent annual cost band is approximately AED 94,000 to 129,000 at list price. Insurance preauthorisation reduces out-of-pocket exposure substantially for covered patients; cash-pay exposure depends on the dispensing pharmacy's regional pricing.
For Emirati nationals with Thiqa coverage, the financial pre-authorisation conversation needs to start before the first dispensing, not after. Daman and other commercial covers vary; the prescribing dermatologist's office is the gating step.
What to monitor
The notable adverse-event class for Adbry is ocular: conjunctivitis (most common) and, less commonly, keratitis. Most cases are mild to moderate and respond to topical treatment. Patients with prior conjunctivitis history may benefit from baseline ophthalmology assessment. New or worsening eye symptoms during treatment warrant prompt review.
Injection-site reactions (redness, swelling, mild pain) are common and typically resolve over time as the patient learns the injection technique.
Live vaccines should be avoided during treatment.
Long-term safety data from the open-label extension trials is reassuring through years 3 to 4 of continuous use; longer-term real-world data continues to accumulate.
Religious, ethical, and family-logistics framing
Adbry is a recombinant IgG4 monoclonal antibody produced in CHO cell lines. There is no donor element, no human or animal source material, and no foreign genetic content in the patient. The classical analogy to vaccines and other injectable biologics holds in MENA Islamic medical ethics, where biologics are generally treated as permissive with the standard expectation that the family decides in consultation with the treating physician.
The self-injection element is the practical pressure point for some UAE families. Patients or family members who are uncomfortable with home injection can request clinic-administered dispensing, though this adds friction. Most UAE patients are comfortable with self-injection after the initial training; the injection is subcutaneous, the syringe is small, and the technique is well-established.
For adolescent patients (12 to 17), parental involvement in the injection routine is typical and culturally expected. Many UAE families designate one parent or close relative as the primary injection support; this is a normal and well-tolerated arrangement.
The chronic-treatment nature of Adbry means a years-long routine. UAE family logistics should plan for cold-chain pharmacy access (most UAE community pharmacies handle this), travel-friendly storage (the 14-day room-temperature window allows for short trips), and dermatology follow-up cadence.
When Adbry is not the right call
For a UAE patient whose AD severity does not meet biologic eligibility thresholds, where the disease is well controlled on topicals or oral cyclosporine short courses, where helminthic infection screening is positive and requires treatment before IL-13 blockade can begin, or where insurance pre-authorisation requires dupilumab trial first (and dupilumab has not yet been tried), the operational pathway shifts:
- Dupixent (dupilumab): anti-IL-4Rα; first biologic for AD; broader indication (6 months and up); most established MENA experience. Often the first-line biologic by physician familiarity. - Ebglyss (lebrikizumab): another IL-13 antagonist; FDA approved September 2024; competing in the same lane as Adbry. - Cibinqo (abrocitinib) and Rinvoq (upadacitinib): oral JAK1 inhibitors; faster onset; boxed warning class. Useful when biologic therapy is contraindicated or when oral administration is preferred over injection. - Continued topical therapy with adjuncts (topical PDE4 inhibitor crisoborole / Eucrisa, topical Janus kinase inhibitor ruxolitinib cream / Opzelura where registered): for mild-to-moderate disease.
Reserve Meds does not push a default. The page above describes the Adbry pathway because Adbry is the biologic the patient has asked about. If the conversation with the treating dermatologist points toward Dupixent, Ebglyss, an oral JAK inhibitor, or continued topical therapy, the operational pathway shifts accordingly.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a UAE Adbry case we build the documentation pack with the treating dermatologist's office, run the insurance pre-authorisation conversation alongside the clinical pre-authorisation conversation, coordinate the cold-chain supply logistics for ongoing maintenance dispensing, organise self-injection training and ophthalmology baseline if needed, and stay with the case through the first year of dosing with handoff to the local dermatologist for ongoing surveillance. Clinical decisions remain with your treating dermatologist.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating dermatologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.